The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback